Sorry fellow members: I have no longer followed this board post by post. It's just waste of time.
I continually add shares as long as the share price, reflected on low market cap of around $200 million in a fully diluted base (today's it's about $100 based on around 440 million shares) is low, because the huge upside potential has not changed, which should be at least in the range from $3 to 10 billion if topline data are released and they are positive:
We already know DCVax-L is safe, pristine safe; and regardless what has happened with the halt, the design, the changes in protocols, the overdue primary and/or secondary endpoints, the baseless accusations, new and old, the message board endless "experts" opinions on everything, real or imaginable, the blatant endless attack on share prices,the DCVax-L will be approved by regulatory authorities, including corrupted FDA (the recent two articles appeared in Science just a couple of days agao are once again testimonies that FDA is just big pharms' toy and it is often against small biotech companies).
If one follows developments in treating GBM, and reads the recent published interim blended results of DCVax-L in treating GBM as of last year, he/she will conclude the chance of DCVax-L shows efficacy is pretty much high, above 80% IMHO.
For a $0.23 per share stock at market cap of slightly over $200 million in a fully diluted base, and an odds of approval of at least more than 50% in treating one of the toughest cancers, all the doubts, bashing, so-called discussions are just pitiful.
The company has said it has been in discussions with regulatory bodies all along since around the temporary halt for new patient screening, and it seems that process is still ongoing, perhaps with some twists and turns, new subjects, new contents, etc.
I trust the company will have definite communications with its investors after that process is complete successfully. If not, I also believe the company will unblind the trial anytime within this year.
And with concrete data showing both safety and efficacy, even the corrupted FDA will have to save its face in the face of light, public opinions backed by solid trial data.
That's day is coming fast! In the meanwhile, Linda has my confidence to surprise the market!
BTW, it is common sense and empirical that a small biotech company will usually launch other trials, in any other indications, in any forms, either combination or not, if it doesn't have confidence its pivotal trial will be a success. Anyone who has invested in small biotech companies knows and see this for at least multiple cases. Linda doesn't have problem to dilute us heavily to launch one or two promised combinational trials if she doesn't have confidence in success of DCVax-L trial. So far she has focused on L, which I am very happy about it.
Does a potential paradigm shifting cancer treatment vaccine deserve only a couple of hundred million market cap!
One must be nuts debating when it is the good entry point, not buying more if still having dry powder to disposal, not covering naked short positions, not giving up useless endless unknown negative motives and actions!
AI
